Systemic scleroderma. Clinical and pathophysiologic aspects.
Systemic scleroderma is a generalized disease of connective tissue involving mainly the skin, the gastrointestinal tract, the lungs, the heart, and the kidneys. It can be present in different forms, of which acroscleroderma, with limited cutaneous and extracutaneous involvement, and diffuse scleroderma within a more rapid progression are most characteristic. Circulating antibodies against antinucleolar antigens are present in most patients with systemic scleroderma. They are helpful for establishing a classification and for determining the prognosis of the disease; their involvement in the pathogenesis, however, is still unclear. Alterations of the blood vessels and induction of fibroblasts by potent mediators are thought to play an important role in the early phase of scleroderma. Therefore early diagnosis is required, which then can initiate vasoactive therapy. In patients with systemic scleroderma, who also suffer from additional myositis, interstitial lung diseases, or arthritis, anti-inflammatory treatment with prednisolone and azathioprine is suggested. Development and progression of fibrosis cannot yet be influenced sufficiently. Only D-penicillamine affecting cross-linking of collagen has been widely used in scleroderma and has some beneficial effect.
Krieg
T
T
Dermatology Clinic and Polyclinic, Ludwig-Maximilian University of München, FRG.
Meurer
M
M
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000302:isolation & purification; D002317:Cardiovascular Agents / Q000627:therapeutic use; D003238:Connective Tissue / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D005260:Female; D006801:Humans; D007107:Immune System / Q000503:physiopathology; D008297:Male; D012595:Scleroderma, Systemic / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology
D000893:Anti-Inflammatory Agents; D001323:Autoantibodies; D002317:Cardiovascular Agents